SENJU PHARMACEUTICAL
Senju Pharmaceutical produces ophthalmic medicine, prescription drugs, and over the counter medicines. Senju Pharmaceutical, as a pioneer of ophthalmic medicine, has always been on the path of originality as a pioneer of ophthalmic medicine under the development policy of giving priority to safety and the sense of mission to serve the eye health of people all over the world. It aims to create excellent medicines and services in the areas of the five senses (visual, auditory, olfactory, taste, and tactile) that are sensor functions that make people feel the joy of living.
SENJU PHARMACEUTICAL
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Apache Euro
Similar Organizations
Acuity Pharmaceuticals
Acuity Pharmaceuticals product-focused ophthalmic pharmaceutical company applying its proprietary technology to the treatment.
Genus Pharmaceuticals
Genus Pharmaceuticals is a pharmaceutical company, sells and markets prescription and over the counter generic medicines.
Merck
Merck is a pharmaceutical and chemical enterprise that develops prescription drugs and over-the-counter products.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-18 | GORYO Chemical | Senju Pharmaceutical investment in Venture Round - GORYO Chemical | 400 M JPY |
| 2018-03-26 | Semathera | Senju Pharmaceutical investment in Venture Round - Semathera | 2.6 M USD |
More informations about "Senju Pharmaceutical"
Research and Development System | Research
Senju Pharmaceutical has unique research systems, such as international joint research and industry-academia joint research, and tackles research and development through a flexible concept without adhering to a conventional โฆSee details»
Overseas Activities | SENJU Pharmaceutical
In China, we established a local subsidiary, Jiangsu Senju Pharmaceutical Co., Ltd., to strengthen our marketing system and steadily lay the groundwork for globalization. Overseas bases. BEIJING OFFICE Beijing, China. 1606B๏ผ16th โฆSee details»
Senju Pharmaceutical - Crunchbase Investor Profile
Senju Pharmaceutical, as a pioneer of ophthalmic medicine, has always been on the path of originality as a pioneer of ophthalmic medicine under the โฆSee details»
SENJU PHARMACEUTICAL CO., LTD. | Member Companies | Japan ...
This page is a SENJU PHARMACEUTICAL CO., LTD. page of JPMA. Address: 3-1-9 Kawara-machi, Chuo-ku, Osaka 541-0048. Contact: Phone๏ผ+81-6-6201-2512See details»
Milestones in Our History | About Senju | SENJU Pharmaceutical
Established a liaison office SENJU PHARMACEUTICAL SCIENCE & TECHNOLOGY (BEIJING) CO., LTD., in Beijing, China, followed by liquidation in July 2011 of Senju Medical Consulting โฆSee details»
Senju USA - Crunchbase Company Profile & Funding
Senju USA is a pharmaceutical company in the field of ophthalmology. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... 9,920 Number of Organizations โข $142.1B Total Funding Amount โข 19,834 โฆSee details»
Senju has successfully completed Phase III clinical trials in Japan โฆ
Senju is committed o obtaint ing marketing approval for the DED treatment SJP-0132 to provide patients with new options for alleviating the signs and symptoms of this disease. Mochida is โฆSee details»
SJP-0008 - Drug Targets, Indications, Patents - Synapse - Patsnap
2 days ago SJP-0008, Initially developed by Senju Pharmaceutical Co., Ltd., Now, its global highest R&D status is Phase 3, Therapeutic Areas: Cardiovascular Diseases,Eye ...See details»
Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign โฆ
Jul 24, 2024 Eyenovia, Inc., a commercial-stage ophthalmic company, has entered into a collaboration agreement with Senju Pharmaceutical Co., Ltd. 1 With the 2 companies joining forces, they intend to work to develop Senjuโs โฆSee details»
Fonadelpar - Senju Pharmaceutical - AdisInsight - Springer
23 Jul 2024 Senju Pharmaceutical and Eyenovia plans to submit new drug application (NDA) for a novel drug-device combination product for Dry eyes ; ... If your organization has a โฆSee details»
Senju Files Mochida-Partnered Dry Eye Drug in Japan
Jan 20, 2025 Senju Pharmaceutical said on January 17 that it filed a new drug application the same day for SJP-0132, a TRPV1 antagonist originated by Mochida Pharmaceutical, in Japan โฆSee details»
Senju Pharmaceutical Co Ltd: Segment Analysis - GlobalData
Senju Pharmaceutical Co Ltd (Senju) develops pharmaceutical products for the care of the five sensory organs: eye, ear, nose, throat and skin. The company categorizes its business into โฆSee details»
Presence of Products | Overseas Activities | SENJU Pharmaceutical
Brand Name Marketing Authorisation Holder JP Brand Name; BRONUCK: Taejoon Pharmaceutical Co., Ltd. BRONUCK: ALYMUS: Taejoon Pharmaceutical Co., Ltd. TALYMUSSee details»
SJP-0132 - Drug Targets, Indications, Patents - Synapse - Patsnap
Jan 23, 2025 SJP-0132, Initially developed by Senju Pharmaceutical Co., Ltd., Now, its global highest R&D status is Phase 3, Therapeutic Areas: Eye Diseases, Active Indication ...See details»
SJP 0132 - AdisInsight - Springer
Jan 24, 2025 04 Dec 2024 Senju Pharmaceutical plans a phase III trial for Dry eyes in China (Ophthalmic, Drops) (NCT06717152) You need to be a logged in or subscribed to view this โฆSee details»
Y 39983 - AdisInsight - Springer
Sep 24, 2021 02 Feb 2018 Y 39983 is still at phase II development stage for Glaucoma and Ocular hypertension in Japan (Ophthalmic) (Senju Pharmaceutical pipeline, February 2018) 30 โฆSee details»
Senju Obtains Approval for Glaucoma Treatment Aiphagan
Senju Pharmaceutical announced on January 18 that the company received on the same day approval for its glaucoma/ocular hypertension treatment Aiphagan Ophthalmic Solution 0.1% โฆSee details»
OTC Products, etc. | Products | SENJU Pharmaceutical
About Senju CEO Message Management Policy Company Profile Our Initiatives for Society/Environment Business Activities Production system Quality policy Overseas Activities โฆSee details»
SJP-0118 - Drug Targets, Indications, Patents - Synapse - Patsnap
2 days ago SJP-0118, Initially developed by Senju Pharmaceutical Co., Ltd., Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms,Eye Diseases.See details»
SNJ-1945 - Drug Targets, Indications, Patents - Synapse - Patsnap
Jan 23, 2025 Cerebral ischemia induces Ca(2+) influx into neuronal cells, and activates several proteases including calpains. Since calpains play important roles in neuronal cell death, โฆSee details»